History
History
Our Journey
1996
Licensed Agreement with F. Hoffmann-La Roche Ltd.
1999 - 2000
Installation, Qualification & Validation
2001 - 2002
Process validation, stability studies
2002
Commercial Production Started.
2005
Agreement signed with NOVARTIS for contract manufacturing.
2009
Launched Cephalosporin products from a dedicated facility.
2010
Launch cream & ointment products from separate facility.
2012
Established a state-of-the-art facility for Small Volume Parenterals, Ophthalmic, Lyophilized, and Biosimilar products.
2013
Established Metered Dose Inhaler (MDI) facility.
2015
Marketing & Distribution agreement with MSD Pharmaceutical, subsidiary of Merck.
2016
Anti-cancer products launch from HPL dedicated oncology facility
2019
Distribution agreement signed with ELI LILLY
2019
Sergel became number one pharmaceutical brand in Bangladesh
2019
HPL achieved TGA EU GMP certification for oral solids
2020
Started dedicated sterile cephalosporin facility
2021
Launched hormone products from HPL dedicated facility
2023
Launched HPL's first product in USA
2025
HPL achieved EU GMP certification for anti-cancer products.